目的:研究艾迪注射液联合FOLFOX4化疗对晚期结肠癌患者肿瘤干细胞特性及抗肿瘤免疫应答的影响.方法:选择在我院接受化疗的晚期结肠癌患者,随机分为接受艾迪注射液联合FOLFOX4化疗的联合化疗组以及单纯FOLFOX4化疗的FOLFOX4组.化疗后,采集血清并测定肿瘤标志物的含量,采集肿瘤病灶并测定肿瘤干细胞标志物以及免疫细胞标志物的表达量,采集外周血单个核细胞并测定免疫细胞标志物的表达量.结果:治疗后2个周期、4个周期时,联合化疗组血清中CEA、CA199、CCSA-3、CCSA-4的含量显著低于FOLFOX4组,外周血单个核细胞中CD3、CD4、CD8、CD16、CD56的平均荧光强度均显著高于FOLFOX4组;化疗后4个周期时,联合化疗组患者肿瘤病灶中CD133、Musashi-1、Piwil2、Nanog、Sox-2的蛋白含量显著低于FOLFOX4组,CD3、CD4、CD8、CD16、CD56的平均荧光强度均显著高于FOLFOX4组.结论:艾迪注射液联合FOLFOX4化疗治疗晚期结肠癌有助于降低肿瘤负荷、抑制肿瘤干细胞特性、增强抗肿瘤免疫应答.%Objective: To study the effecof Aidi injection combined with FOLFOX4 chemotherapy on tumostem cell characteristicand antitumoimmune response in patientwith advanced colon cancer.Methods: Patientwith advanced colon cancewho received chemotherapy in ouhospital between May 2013 and June 2016 were selected and randomly divided into the combined chemotherapy group who received Aidi injection combined with FOLFOX4 chemotherapy and the FOLFOX4 group who received FOLFOX4 chemotherapy alone.Aftechemotherapy, the serum wacollected to determine the levelof tumomarkers, tumolesionwere collected to determine the expression of tumostem cell markerand immune cell markers, and peripheral blood mononucleacellwere collected to determine the expression of immune cell markers.Results: Afte2 and 4 cycleof treatment, serum CEA, CA199, CCSA-3 and CCSA-4 levelof combined chemotherapy group were significantly lowethan those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 in peripheral blood mononucleacellwere significantly highethan those of FOLFOX4 group;aftefoucycleof chemotherapy, CD133, Musashi-1, Piwil2, Nanog and Sox-2 protein contenin tumolesionwere significantly lowethan those of FOLFOX4 group, and the mean fluorescence intensity of CD3, CD4, CD8, CD16 and CD56 were significantly highethan those of FOLFOX4 group.Conclusions: Aidi injection combined with FOLFOX4 chemotherapy treatmenof advanced colon cancewill help reduce the tumoload, inhibitumostem cell characteristicand enhance antitumoimmune response.
展开▼
